StressGen jumps 18% on virus test results

Article Abstract:

Victoria, BC-based StressGen Biotechnologies Corp. announced that it achieved positive results from clinical tests of a drug that will be used to treat a common sexually transmitted diseases. StressGen's share price rose 18% on news of the breakthrough.

Biological products exc. diagnostic, Vaccines for Human Use, Vaccines industry, Biological products industry, Vaccines, Sexually transmitted disease vaccines, StressGen Biotechnologies Corp.

---

Adherex makes plans to market IPO

Article Abstract:

Adherex Technologies Inc., which is a drug development company, has announced plans to launch a $20 million initial public offering. Adherex is developing a new anti-cancer drug, called Exherin, that is designed to reduce blood vessels that feed tumors.

Anticancer Drugs, Finance, Antineoplastic agents, Adherex Technologies Inc.

---

Labopharm feels market pain from delayed approval of new drug

Article Abstract:

Effects of delay in approval of new pain-killing drug by United States Food and Drug Administration, on stock prices of Labopharm Incorporated, are described.

Drugs & Pharmaceuticals, Pharmaceutical and Medicine Manufacturing, Drugs, Metabolic Agents NEC, Metabolic Agents, United States, Beliefs, opinions and attitudes, Company sales and earnings, Company earnings/profit, United States. Food and Drug Administration, Labopharm Inc.

Similar abstracts:

• Abstracts: Sears fails to gain much ground with lackluster profit report. Bay, Zellers shoppers to be wooed in 'cross-shopping' plan
• Abstracts: Award-winning Shift magazine awaits fate after finances dry up. U.S. drug officials vetted TV shows' plot lines
• Abstracts: Canadians red-faced as Russians make a farce of bankruptcy law. Recovering Russia lures investor group

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.